Description:
Parasitic (e.g., malaria, African trypanosomiasis, leishmaniasis), bacterial (e.g., tuberculosis, leprosy), and viral diseases (e.g., rabies, Dengue fever, Chikungunya, Ebola) still kill 2.5 M people annually, and create misery and suffering for countless hundreds of millions worldwide. Sadly, infectious diseases affecting >1 Bn people in developing countries attract little donor funding, because those diseases are rare in wealthy, largely non-tropical countries. The cost of bringing a new drug to market is approximately US$2 Bn and pharmaceutical companies need to recoup this large, high-risk investment through the cost of the drug. Although the market is very large for NTDs, the ability of individuals or governments to pay for drugs is a major barrier to their development and sale. Philanthropic organizations such as the Bill and Melinda Gates Foundation, Stop TB Partnership, and the Medicines for Malaria Venture aim to bridge this gap

URL:
http://103.158.96.210:88/web_repository/uploads/ps-29-395.pdf

Type:
Journal

Document:
Diploma III Farmasi

Date:
23-06-2024

Author:
David Alan Winkler